Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2590MR)

This product GTTS-WQ2590MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2590MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9347MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ12059MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ2742MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ6064MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ13437MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ15911MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ7192MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ12933MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PankoMab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW